Table 2.
Neuroimaging measures and cognitive decline
| Neuroimaging measure | Standardized β | T statistic | p value |
|---|---|---|---|
| PiB | |||
| Decliner | −.01 | −.08 | .939 |
| Age | .35 | 3.83 | <.001 |
| Female | .21 | 2.40 | .018 |
| APOE4 positive | .10 | 1.07 | .286 |
| FH positive | .04 | .42 | .674 |
| FDG | |||
| Decliner | −.04 | −1.69 | .093 |
| Age | −.06 | −2.32 | .022 |
| Female | −.10 | −3.71 | <.001 |
| APOE4 positive | −.01 | −.44 | .664 |
| FH positive | .01 | .41 | .684 |
| FDG global | 1.00 | 36.19 | <.001 |
| fMRI | |||
| Decliner | .15 | 1.65 | .100 |
| Age | .06 | .65 | .518 |
| Female | .12 | 1.32 | .189 |
| APOE4 positive | .01 | .03 | .976 |
| FH positive | .23 | 2.51 | .013 |
| Hippocampal volume | |||
| Decliner | .04 | .55 | .587 |
| Age | −.29 | −3.63 | <.001 |
| Female | −.05 | −.53 | .601 |
| APOE4 positive | .01 | .08 | .94 |
| FH positive | .09 | 1.10 | .273 |
| ICV | .44 | 4.44 | <.001 |
For each imaging measure, all predictors were entered in the regression model simultaneously.
PiB= Pittsburgh Compound B; FDG= fluorodeoxyglucose; fMRI=functional magnetic resonance imaging; APOE4=the varepsilon 4 allele of the apolipoprotein E gene; FH=family history of Alzheimer’s disease; ICV=intracranial volume.